Largest childhood preventative health initiative in nearly 20 yearsBeyfortus rollout to ensure all babies are RSV protected this winterThe largest ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

For the first time, RSV immunisation is now available to Western Australians both during pregnancy, and for eligible babies ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

Learn more about whether AstraZeneca PLC or Corcept Therapeutics Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In its first full year, Dupixent made almost €13 billion, while Beyfortus, a new RSV vaccine for infants, made €1.7 billion and became a blockbuster. Despite a 1.8% drop in reported terms ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...

Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

It believes that its three new products launched/added in 2023, Altuviiio (for hemophilia A), Beyfortus (for RSV) and Tzield (for type 1 diabetes), together can add up to at least €5 billion in ...